سامية محمد مصطفى



شبكة المعلومات الحامعية

بسم الله الرحمن الرحيم



-Caro-

سامية محمد مصطفي



شبكة العلومات الحامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





سامية محمد مصطفى

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسو

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار



سامية محمد مصطفي



شبكة المعلومات الجامعية



المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة عين شعور المسلمة ا

سامية محمد مصطفى

شبكة المعلومات الحامعية



بالرسالة صفحات لم ترد بالأصل



B 07 19

Clinical and Sonographic Assessment of the Side Effects of Intracavernosal Injection of Vasoactive Substances

A Thesis
Submitted for the partial fulfillment of Master degree in Dermatology,
Andrology and STDs

By

Rany Mohamed Mahmoud M.B.B.C.H

Supervisors:

Prof. Dr. Mohamed Nabil Moemen Professor of Andrology & STDs

Professor of Andrology & STDs
Faculty of Medicine, Cairo university

Prof.Dr. Hamed Abdallah Hamed

Assistant Professor of Andrology & STDs Faculty of Medicine, Cairo university

Dr. Ihab Ismail Kamel

Lecturer of Andrology & STDs Faculty of Medicine, Cairo university

Faculty of Medicine, Cairo university

2002

B MEVI

محضر اجتماع لجنه الحكم على الرسياله المتدمه من اليابيب/ سأتى محرمود سيحلول:

(۱) توطئه لدخوله امتحان الدكتوراه في : ۰۰۰۰۰۰۰ معموم و دولته المتحان الدكتوراه في

(١) كبيرة بن الدرة الثاني لاحتمان الماج سيستيرن: المعراهم كم ليربر ولمعالم مرابع.

اجتمعت لم نه الحكم على الرسالة التكونة بن السادة : ـــ

الاستاذ الدائتور المحد نيل مؤمم - استاد الإمام (الآراه ولئنا ل (المراح في الاستاذ الدائتور / راهم وربن - ساد الدائتور / راهم وربن - ساد الدائتور / مرسلوام عيدارى - استاذ الدائتور المرسلوام الاستاد الدائم و المرسلور المرسلورية الرسلورية المرسلورية الم

ثم ناقفه السادة أضاء لجنة الحكم في

وقررعاالل فسندال

Initio estima

استاذ دکتور لبر[هم *ارفوی* ا بالمزار استاذ داتور مرمبل مؤسم مرمبل مؤسم

Abstract

The aim of this work was to evaluate the side-effects of intracavernous vasoactive agents on clinical and Sonographic basis. Two groups were included, Group I included 305 patients, 40 to 60 years old, complaining of ED who were trained for self-injection therapy with one of three protocols: protocol A papaverine, protocol B PGE1 and protocol C trimix(papaverine, phentolamine, and PGE1). They were then followed-up clinically, sonographically and by laboratory investigations for 6 months to evaluate the occurrence of side-effects of ICI. Group II included 21 patients presenting to our department for the first time with one of the complications of ICI received elsewhere. They were evaluated and managed accordingly.

One hundred and sixty-eight patients of group I completed the study. Patients on protocol A had the highest incidence of complications concerning priapism, subcutaneous hematoma and penile fibrosis. Postinjection penile pain was observed more with PGE1 and trimix than papaverine. No systemic side-effects were reported. Duplex ultrasound proved beneficial in clarifying fibrosis which was clinically undetectable. Ten patients of group II complained of priapism. Four of whom received the injection during dynamic duplex study, another four received it in private clinics of specialized doctors, while the last two received it at a pharmacy. Seven patients(of group II) complained of penile fibrosis, three of cavernositis and one of intracavernous needle breakage. While Side-effects of ICI are more common with papaverine, PGE1 has the highest incidence of postinjection penile pain.. Duplex ultrasound showed considerable value in detection of penile fibrosis. Performing intracavernous injection and training patients to self-inject themselves should be supervised by an andrologist. Regular follow-up of patients on intracavernous self-injection therapy clinically and sonographically is mandatory. There is a great need for safer intracavernosal vasoactive agents with less invasive delivery systems.

<u>Keywords:</u> erectile dysfunction, intracavernosal pharmacotherapy, intracavernosal agents, side-effects of ICI.

Acknowledgement

"First and foremost, thanks are due to God, the Beneficent and Merciful".

I am most grateful to Prof. Dr. Mohamed Nabil Moemen, Professor of Andrology & STDs, faculty of Medicine, Cairo university, who kindly supervised and motivated the performance of this work with zealous interest and borderless advice.

With great honor, I express my sincere gratitude to Prof. Dr. Hamed Abdallah Hamed, Assistant professor of Andrology & STDs, faculty of Medicine, Cairo university, for his kind supervision, ardent encouragement and precious time. Words are not enough to recognize his effort, help and care he gave me throughout this work. I hope that these few lines could express my great appreciation and sincere gratitude to him.

Much more than thanks to Dr. Ihab Ismail Kamel, lecturer of Andrology & STDs, faculty of Medicine, Cairo university, for his valued scientific guidance.

I would like to express my deep appreciation and gratitude to all my professors and colleagues in the department of Andrology \$ STDs, faculty of Medicine, Cairo university for their thoughtful help and support.

This is a place I have been awaiting to thank my dear parents and sister in pen and paper. Their endless support encouraged me throughout this work.

Finally, I wish to express my sincere gratitude to all the patients who helped this work to be done.





Table of Contents

| List of Abbreviations I |
|---|
| List of Tables II |
| List of Figures III |
| Introduction and Aim of Work 1 |
| Review: |
| • CHAPTER 1 Intracavernosal pharmacotherapy 3 |
| CHAPTER 2 Side-effects of Intracavernosal Drugs18 |
| Chapter 3 Penile Duplex 46 |
| Patients and Methods 59 |
| Results 68 |
| Discussion 78 |
| Summary and Conclusion 86 |
| References 89 |
| Arabic Summary |



List of Abbreviations

IC Intracavernous

ICI Intracavernous Injection

ED Erectile Dysfunction

CGRP Calcitonin gene related peptide

VIP Vasoactive intestinal peptide

cAMP Cyclic adenosine monophosphate

cGMP Cyclic Guanylate monophosphate

PGE1 Prostaglandin E1

NANC Non-adrenergic Non-cholinergic

CNS Central nervous system

NO Nitric Oxide

CDDU Color Doppler Duplex Ultrasound

PPDU Pharmacopenile Doppler Ultrasound

RI Resisitivity Index


PSV Peak Systolic Velocity

EDV End Diastolic Velocity

IIEF International Index of Erectile Function

CBC Complete Blood Count

LFTs Liver Function Tests



Lists of Tables

| Table (1) Risk factor in the papaverine group69 |
|--|
| Table (2) Risk factor in the PGE1 group69 |
| Table (3) Risk factor in the Trimix group 70 |
| Table (4) Incidence of priapism with different vasoactive drugs70 |
| Table (5) Incidence of priapism with different vasoactive drugs |
| according to the dose70 |
| Table (6) Incidence of penile pain among patients in different |
| groups fibrosis among patients in different groups71 |
| Table (7) Relation between risk factors and penile pain71 |
| Table (8) Incidence of penile fibrosis detected clinically72 |
| Table (9) Incidence of penile fibrosis detected sonographically 72 |
| Table (10) Incidence of penile fibrosis according to the dose 73 |
| Table (11) Site of penile fibrosis as detected by penile ultrasound 73 |
| Table (12) Relation between risk factors and penile fibrosis 74 |
| Table(13) Relation between the frequency of injection |
| and the development of penile fibrosis 74 |
| Table (14) Time elapsing from injection till presentation 75 |